Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy
Authors
Keywords
Advanced gastric cancer, Serum HER2, Extracellular domain (ECD), Trastuzumab
Journal
JOURNAL OF GASTROENTEROLOGY
Volume 50, Issue 9, Pages 955-961
Publisher
Springer Nature
Online
2015-02-21
DOI
10.1007/s00535-015-1046-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
- (2014) Zhi Peng et al. Biomarkers in Medicine
- A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
- (2014) Carlos Gomez-Martín et al. CANCER LETTERS
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- HER2 Directed Therapy for Gastric/Esophageal Cancers
- (2014) Elizabeth Won et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Erratum to: Evaluation of serum HER2-ECD levels in patients with gastric cancer
- (2014) Katsunobu Oyama et al. JOURNAL OF GASTROENTEROLOGY
- Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer
- (2013) Eva Rabing Brix Petersen et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- HER2-positive gastric cancer
- (2013) Narikazu Boku Gastric Cancer
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum human epidermal growth factor receptor 2 levels as a real-time marker for tumor burden in breast cancer patients
- (2013) Hyun-Ah Kim et al. JOURNAL OF SURGICAL ONCOLOGY
- Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma
- (2013) Shu-Qin Dai et al. PLoS One
- Activity and resistance of trastuzumab according to different clinical settings
- (2011) Elda Tagliabue et al. CANCER TREATMENT REVIEWS
- Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
- (2011) Brian Leyland-Jones et al. LANCET ONCOLOGY
- Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
- (2010) Isabell Witzel et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
- (2008) Suhail M. Ali et al. CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now